This volume comprises five authoritative reviews on timely topics in drug research. The first two chapters deal with chemotherapeutic agents (selective antiviral agents and cepham antibiotics) and subsequent chapters deal with the cardiovascular system and topics in neuropharmacology.

After thirty five years, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition is still the reference of choice for comprehensive, global guidance on diagnosing and treating the most challenging infectious diseases. Drs. John E. Bennett and Raphael Dolin along with new editorial team member Dr. Martin Blaser have meticulously updated this latest edition to save you time and to ensure you have the latest clinical and scientific knowledge at your fingertips. With new chapters, expanded and updated coverage, increased worldwide perspectives, and many new contributors, Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Edition helps you identify and treat whatever infectious disease you see. Get the answers to any questions you have with more in-depth coverage of epidemiology, etiology, pathology, microbiology, immunology, and treatment of infectious agents than you’ll find in any other ID resource. Apply the latest knowledge with updated diagnoses and treatments for currently recognized and newly emerging infectious diseases, such as those caused by avian and swine influenza viruses. Put the latest knowledge to work in your practice with new or completely revised chapters on Influenza (new pandemic strains); New Middle East Respiratory Syndrome (MERS) Virus; Probiotics; Antibiotics for resistant bacteria; Antifungal drugs; New Antivirals for hepatitis B and C; Clostridium difficile treatment; Sepsis; Advances in HIV prevention and treatment; Viral gastroenteritis; Lyme Disease; Helicobacter pylori; Malaria; Infections in immunocompromised hosts; Immunization (new vaccines and new recommendations); and Microbiome. Benefit from fresh perspectives and expanded global insights from an expanded team of American and International contributors. Martin Blaser, MD, a leading expert and Muriel G. and George W. Singer Professional of Translational Medicine at New York University School of Medicine, joins veteran PPID editors John E. Bennett, MD, and Raphael Dolin, MD to continue a legacy of excellence. Find and grasp the information you need easily and rapidly with newly added chapter summaries.

This book focuses on topics ranging from the economics of drug-resistant infections and the management of antimicrobial use to new information on methods to optimize the selection, route of administration, dosing, and duration of antimicrobial therapies for common infections. In addition to offering ideas on studied programmatic approaches for judi

5t The 1 International Moxifloxacin symposium took place in Berlin Germany February 18 - 20,1999. The purpose of this meeting was to introduce the medical and scientific communities to this exciting new fluoroquinolone and to define its role in the management of respiratory tract infections. The fluoroquinolones as a class are an important part of our therapeutic armamentarium and moxi floxacin is a unique addition to this class of compounds. This symposium brought together physician/scientists from around the world to present and discuss the moxifloxacin data. The information from this important meeting are presented in these proceedings and are organized under the following headings: Part I Antimicrobial chemotherapy Part II Pre-clinical microbiology Part III Pharmacology Part IV Clinical needs in the millennium Part V Round table discussion The modifications to the basic quinolone structure resulting in moxifloxacin have produced a drug with unique in vitro, and pharmacokinetic/pharmaco dynamic properties. The drug has a very broad spectrum of antimicrobial activity, is well absorbed and can be taken only once daily. Its profile makes it an excellent therapeutic option for many types of respiratory tract infections. It is hoped that our clinical and laboratory colleagues will be as excited by this data as we are and we look forward to further work with this unique and interesting compound.

Recent evidence suggests an increasing rate of antimicrobial resistant pathogens throughout the world. Pathogens like Staphylococcus aureus are showing substantial prevalence of resistance to antibiotics. Thus, we think that given these developments, clinicians would welcome an updated version of this book. A resource indicating appropriate, evidence-based antimicrobial treatment of infectious diseases encountered in both the hospital and outpatient settings would be of significant value to practicing clinicians. The book would focus on the clinical importance of appropriate diagnosis and treatment of infectious diseases particularly in terms of antibiotic-resistance. The resource would be valuable to countless numbers of junior-level practitioners (residents, nurse practitioners, physician-assistants). Moreover, the book could be a resource for generalists as well as infectious disease specialists.